This page shows the latest financial results 2012 news and features for those working in and with pharma, biotech and healthcare.
Profits have declined since 2008, however, when Teva and Barr Pharmaceuticals won a patient challenge to launch their own generic copy, and Nasacort AQ achieved revenues of just 71m during 2012 ... This is part of a wider plan to build its consumer
Sales fell almost 10 per cent in the quarter to 8bn ($10.6bn), with around 480m lost to generic competition compared to the same period of 2012 and inventory mismanagement in ... at 760m the unit suffered from comparison with the same period in 2012
Sales and profits on track amid job cuts and restructuring. Germany's Merck KGaA successfully navigated a tricky path in 2012 as it kept sales and profits on target, despite ... The restructuring programme is already yielding results in terms of Merck's
to 39.8bn for 2012. ... This helped overcome a decline in sales of the Yaz contraceptive franchise, which lost patent exclusivity during 2012.
yesterday to discuss the deal and Mylan's fourth-quarter results. ... The agreement comes as Mylan reported record financial results in 2012, with revenues up 14 per cent to $6.8bn on the back of 600 product launches around the world, and
Speaking at the presentation of the Belgium-based pharma company's 2012 financial results, Doliveux (pictured) said the ongoing debate over transparency was of little interest outside the UK, and that
More from news
Approximately 17 fully matching, plus 8 partially matching documents found.
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...